Penicillin G (Benzathine, Procaine)

Penicillin G represents the original member of the penicillin antibiotic family, discovered by Alexander Fleming in 1928 and developed into the first widely available antibiotic during the 1940s. In veterinary medicine, penicillin G remains a cornerstone antimicrobial therapy for food-producing animals, valued for its excellent activity against gram-positive bacteria, favorable safety profile, and economical cost. Two principal salt forms extend its duration of action for practical use: procaine penicillin G provides intermediate duration, while benzathine penicillin G offers prolonged activity. Combination products containing both salts provide both rapid onset and sustained therapeutic levels, making penicillin G formulations adaptable to diverse clinical needs in cattle, swine, sheep, goats, and horses.

The mechanism of action of penicillin G involves binding to penicillin-binding proteins (PBPs) located in bacterial cell membranes, thereby inhibiting the transpeptidation reaction essential for peptidoglycan cross-linking in cell wall synthesis. Without intact cell walls, bacteria cannot maintain structural integrity against osmotic pressure, leading to cell lysis and bactericidal killing. This mechanism targets a uniquely bacterial structure absent in mammalian cells, accounting for penicillin's excellent safety profile in treated animals. Susceptible organisms are killed during active growth phases when cell wall synthesis is occurring.

Penicillin G formulations for food animal use are designed as injectable suspensions that provide controlled drug release from intramuscular or subcutaneous injection sites. Procaine penicillin G combines penicillin with procaine to form a crystalline complex with reduced water solubility, creating an intramuscular depot that releases active drug over 12-24 hours. Benzathine penicillin G combines penicillin with dibenzylethylenediamine, producing an even less soluble complex that releases drug over several days. Combination products leverage both salts to provide rapid attainment of therapeutic concentrations from the procaine component while the benzathine component maintains prolonged effect.

Regulatory approval for penicillin G covers numerous indications across multiple food animal species, reflecting decades of clinical use and established safety and efficacy. Some formulations are available over-the-counter while others require veterinary prescription, depending on product labeling and regulatory jurisdiction. Regardless of prescription status, penicillin G use in food animals carries the same responsibilities for accurate dosing, proper administration, and strict withdrawal time observance as any antimicrobial. The drug's long history provides extensive experience informing appropriate therapeutic application while demanding continued responsible use to preserve its effectiveness.

Clostridial infections in cattle represent one of the most important indications for penicillin G, as these gram-positive anaerobic bacteria remain highly susceptible to natural penicillins. Blackleg caused by Clostridium chauvoei, malignant edema from Clostridium septicum and Clostridium novyi, and tetanus from Clostridium tetani all respond to penicillin G when treatment is initiated early in the disease course. These rapidly progressive, often fatal infections require prompt antibiotic therapy combined with supportive care. Penicillin G's consistent activity against clostridia and its ability to achieve therapeutic tissue concentrations make it the antibiotic of choice for clostridial diseases in ruminants.

Respiratory infections in cattle and swine caused by gram-positive organisms constitute another therapeutic application for penicillin G. Streptococcus pneumoniae, Streptococcus pyogenes, and other streptococcal species causing pneumonia typically remain susceptible. However, the mixed bacterial etiology of many respiratory disease complexes limits penicillin G's utility as monotherapy, since gram-negative pathogens like Mannheimia haemolytica and Pasteurella multocida are not reliably covered. Penicillin G may serve as targeted therapy when gram-positive organisms are confirmed or as part of combination treatment protocols addressing both gram-positive and gram-negative components of polymicrobial infections.

Swine erysipelas caused by Erysipelothrix rhusiopathiae responds well to penicillin G therapy, reflecting the organism's consistent susceptibility to beta-lactam antibiotics. This important swine disease manifests as acute septicemia, characteristic diamond skin lesions, or chronic arthritis and endocarditis. Early penicillin G treatment of acute erysipelas produces rapid clinical improvement and is often combined with anti-inflammatory therapy for fever and discomfort. The bactericidal action of penicillin G helps clear the organism before chronic sequelae develop in joints or heart valves.

Actinomycosis (lumpy jaw) and actinobacillosis (wooden tongue) in cattle are caused by Actinomyces bovis and Actinobacillus lignieresii respectively, with the gram-positive Actinomyces species responding to penicillin G therapy. Extended treatment courses may be required for established lesions, and surgical drainage of abscesses complements antibiotic therapy. The chronic, granulomatous nature of these infections demands prolonged therapeutic coverage, making combination procaine-benzathine penicillin products particularly suitable for their extended duration of action between doses.

Wound infections, abscesses, and soft tissue infections involving gram-positive bacteria commonly warrant penicillin G treatment. Streptococcal and staphylococcal wound infections, naval ill in neonates, and post-surgical or post-traumatic infections may respond to penicillin therapy when susceptible organisms are involved. Notably, many staphylococcal strains now produce beta-lactamase and are resistant to penicillin G, requiring susceptibility confirmation or selection of beta-lactamase-resistant alternatives for suspected staphylococcal infections. Despite this limitation, penicillin G remains appropriate for streptococcal and other non-penicillinase-producing gram-positive infections.

Dosing of penicillin G in food animals follows weight-based protocols calibrated to achieve therapeutic concentrations against susceptible pathogens. For cattle, the typical dose of procaine penicillin G is 6,600 to 22,000 IU/kg (3,000-10,000 IU/lb) body weight administered intramuscularly once daily for 3-7 days. Severe or life-threatening infections warrant the higher end of the dosing range and possibly more frequent administration. Combination products containing both procaine and benzathine penicillin may be administered at 48-72 hour intervals due to the extended activity of the benzathine component, reducing handling requirements while maintaining therapeutic coverage.

Swine dosing protocols generally parallel cattle recommendations on a body weight basis, with procaine penicillin G administered at 6,600-22,000 IU/kg intramuscularly daily. For swine erysipelas, prompt treatment at the higher dose range is indicated given the acute nature of the disease. Young pigs and gilts may require more frequent assessment and potential dose adjustment based on clinical response. Mass treatment of affected groups may be necessary during erysipelas outbreaks, with individual severely affected animals requiring more intensive supportive care alongside antibiotic therapy.

Sheep and goats receive penicillin G at doses comparable to cattle on a per-kilogram basis. Treatment of clostridial diseases, footrot, and other susceptible infections follows similar principles as in cattle. The smaller body size of small ruminants means smaller absolute drug volumes, but concentration and frequency calculations remain consistent with larger ruminant protocols. Some clinicians use somewhat higher doses in goats based on potentially faster drug metabolism in this species, though definitive pharmacokinetic data supporting routine dose escalation is limited.

Injection technique influences both drug absorption and animal welfare. Intramuscular injection in the neck region is preferred over hindquarter sites to avoid injection lesions in valuable carcass areas. Needle size should be appropriate for animal size and injection depth, typically 16-18 gauge and 1-1.5 inches for adult cattle. Injection volumes should not exceed 10-15 mL per site, with larger doses divided between multiple sites. Subcutaneous administration is acceptable for some penicillin products and may reduce local tissue reaction compared to intramuscular injection while providing adequate drug absorption.

Shaking the product thoroughly before drawing each dose ensures uniform suspension of the crystalline drug particles and consistent dosing between injections. Penicillin suspensions settle over time, and failure to resuspend can result in initial doses being subtherapeutic while later doses from the same bottle contain excess drug. Visual inspection confirms uniform appearance without clumping or precipitation before administration. Using clean needles and aseptic technique prevents contamination of multi-dose vials.

Withdrawal times for penicillin G vary by formulation, species, and route of administration, requiring careful attention to specific product labeling. Procaine penicillin G in cattle typically requires 4-10 days meat withdrawal depending on the product. Benzathine-containing combination products require longer withdrawals, often 30 days or more, reflecting the extended drug release from these formulations. Milk withdrawal for dairy cattle is typically 48-96 hours for procaine products but considerably longer for benzathine-containing formulations. Animals must not enter the food supply until full withdrawal periods are observed, and treatment records must document dates, products, and calculated withdrawal endpoints.

Penicillin G demonstrates excellent safety in food-producing animals when administered according to label directions, benefiting from decades of clinical experience confirming its favorable therapeutic index. The selective toxicity for bacterial cell wall synthesis rather than mammalian cellular processes underlies the wide margin between therapeutic and toxic doses. Nevertheless, adverse effects can occur and warrant awareness for appropriate monitoring and management. The overall benefit-risk profile strongly favors penicillin G use for susceptible infections when proper protocols are followed.

Injection site reactions represent the most common adverse effect of intramuscular penicillin G administration. Local tissue irritation causes swelling, firmness, and occasionally pain at injection sites, particularly with oil-based or highly concentrated formulations. These reactions typically resolve over days to weeks but may persist as sterile abscesses or fibrous scar tissue in some cases. Injection site lesions can result in carcass trimming at slaughter, representing economic loss. Using appropriate needle technique, limiting injection volumes, and selecting neck rather than hindquarter injection sites helps minimize these complications.

Procaine reactions can occur because procaine penicillin G releases procaine, a local anesthetic, during drug dissolution. Inadvertent intravascular injection of procaine-containing penicillin produces rapid-onset central nervous system effects including hyperexcitability, muscle tremors, ataxia, and in severe cases, collapse. These reactions are transient, typically resolving within 15-30 minutes as procaine is metabolized. Aspirating before injection to confirm the needle is not in a blood vessel significantly reduces procaine reaction risk. If a reaction occurs, the animal should be kept calm and allowed to recover without forced handling that could cause injury.

Hypersensitivity reactions to penicillin range from mild urticaria to life-threatening anaphylaxis. Animals with previous penicillin exposure may have developed allergic sensitization, placing them at risk for reactions on subsequent exposure. Clinical signs may include hives, facial swelling, respiratory distress, salivation, and cardiovascular collapse in severe anaphylaxis. True allergic reactions to penicillin in food animals are uncommon but require immediate intervention with epinephrine when they occur. Animals experiencing hypersensitivity should be identified and documented to prevent future penicillin administration.

Gastrointestinal effects from penicillin G are generally minimal due to parenteral administration that bypasses the gastrointestinal tract. However, high systemic antibiotic levels may occasionally affect intestinal microflora, particularly in monogastric species like swine. Ruminants are relatively protected from direct gut effects because penicillin G is largely inactivated in the rumen when administered parenterally and absorbed systemically. Any diarrhea or intestinal disturbance following penicillin treatment is usually mild and transient.

Penicillin G is contraindicated in animals with documented hypersensitivity to penicillin antibiotics. Previous allergic reactions to any penicillin-class antibiotic establish elevated risk for reactions on subsequent exposure, potentially more severe than initial sensitization events. Animals with known penicillin allergy should receive alternative antibiotics from non-beta-lactam classes. When treatment history is unavailable and urgent therapy is needed, having epinephrine available during initial dosing provides emergency response capability for unexpected anaphylaxis.

Intravascular injection of procaine penicillin G is contraindicated due to the risk of acute procaine toxicity. While procaine released gradually from intramuscular depot sites is absorbed without incident, rapid intravascular delivery produces central nervous system effects including excitation, tremors, and potential collapse. Proper injection technique including aspiration before injection confirms extravascular needle placement and prevents inadvertent intravascular administration. If aspiration withdraws blood, the needle should be repositioned before injecting.

Proximity to slaughter without adequate time for withdrawal period completion contraindicates penicillin G use in food animals. Animals expected to go to slaughter before withdrawal times can be observed should not receive treatment, as violative residues would result in carcass condemnation and regulatory consequences. The extended withdrawal times for benzathine-containing products particularly limit their use in animals near market weight or scheduled for slaughter within weeks of treatment need.

Use in lactating dairy cattle requires careful consideration of milk withdrawal requirements. Penicillin G residues in milk render it unmarketable during treatment and the withdrawal period. Operations must have systems to identify treated cows and segregate their milk from the bulk tank. If milk segregation cannot be reliably accomplished, penicillin G treatment of lactating dairy cattle is effectively contraindicated by practical rather than pharmacological limitations. Dry cow treatment is an alternative timing that avoids milk marketing conflicts.

Bacteriostatic antibiotics including tetracyclines, macrolides, and phenicols may antagonize the bactericidal action of penicillin G through their mechanism of inhibiting bacterial protein synthesis. Since penicillin G requires active bacterial cell division and wall synthesis for optimal effect, concurrent bacteriostatic therapy may reduce killing efficiency. The clinical significance of this interaction varies depending on the infection type, pathogen, and host factors. Generally, simultaneous administration of bacteriostatic and bactericidal antibiotics is avoided unless specifically indicated by established treatment protocols or necessitated by mixed infection scenarios.

Aminoglycoside antibiotics can be combined with penicillin G for synergistic bactericidal effect against certain pathogens. This combination is particularly valuable for serious infections caused by enterococci and some streptococci where neither agent alone achieves reliable bactericidal activity. The synergy results from penicillin-induced cell wall damage enhancing aminoglycoside penetration into bacteria. However, these drugs should not be mixed in the same syringe due to physical incompatibility that can inactivate both agents. Separate injection sites and potentially staggered timing optimize the synergistic benefit.

Nonsteroidal anti-inflammatory drugs are frequently co-administered with penicillin G for treating infections accompanied by fever, pain, or inflammation. No significant pharmacokinetic or pharmacodynamic interactions exist between penicillin and NSAIDs, and the combination provides complementary therapeutic benefits. Flunixin meglumine, meloxicam, and other veterinary NSAIDs may be used concurrently with appropriate attention to withdrawal times for all administered medications.

Probenecid inhibits renal tubular secretion of penicillin, prolonging its half-life and maintaining higher blood levels for extended periods. While this interaction is therapeutically exploited in human medicine, probenecid use in food animals is uncommon, limiting practical relevance of this interaction. Other drugs affecting renal function could theoretically alter penicillin elimination, but clinical significance in food animal practice is minimal given the drug's established safety record even at elevated concentrations.

Human safety during penicillin G handling requires attention to potential allergic sensitization and reaction risk. Individuals with known penicillin allergy should not handle or administer penicillin products. Skin contact with concentrated penicillin solutions can cause sensitization in previously non-allergic individuals or trigger reactions in sensitized persons. Wearing gloves during product handling and administration provides protective barrier. Accidental self-injection constitutes a medical emergency requiring immediate medical attention, with product information provided to healthcare personnel. Eye contact should be avoided and immediate flushing performed if exposure occurs.

Food safety compliance demands strict adherence to species-specific and product-specific withdrawal times. Meat withdrawal times range from 4-30 days or more depending on formulation, requiring careful product selection and timing relative to expected slaughter dates. Milk withdrawal times must be observed for all dairy cattle treatments, with milk from treated cows diverted from the bulk tank until withdrawal completion. Treatment records must document animal identification, product name and concentration, dose, dates of treatment, and calculated withdrawal endpoint. These records support regulatory compliance verification and traceback if residue questions arise.

Antimicrobial resistance considerations influence penicillin G use decisions. While many target pathogens remain susceptible, resistance mediated by beta-lactamase production has emerged in some bacterial populations, particularly staphylococci. Empiric penicillin G therapy may fail against beta-lactamase-producing strains, and culture with sensitivity testing helps identify resistance when treatment response is inadequate. Responsible use including appropriate dose selection, completing treatment courses, and avoiding unnecessary treatment supports maintaining penicillin effectiveness for future needs.

Injection technique affects both efficacy and carcass quality. Neck muscle injection rather than hindquarter sites prevents injection lesions in valuable carcass portions. Appropriate needle size and injection volume limits reduce tissue damage. Rotating injection sites between treatments allows previous injection sites to heal. Aspiration before injection prevents intravascular administration with associated procaine reaction risk. These technique elements optimize therapeutic outcomes while minimizing adverse consequences of treatment.

Storage and handling practices maintain product integrity and prevent contamination. Multi-dose vials should be dated upon first use and discarded after the labeled period or 28 days, whichever is shorter. Contaminated or visually abnormal products should not be used. Maintaining the cold chain for products requiring refrigeration ensures potency is maintained through the expiration date.

Storage requirements for penicillin G products vary by formulation, with most products stable at controlled room temperature. Typical storage temperature is 20-25°C (68-77°F), protected from excessive heat that could accelerate degradation. Refrigeration may extend stability for some products but is not typically required for commercial veterinary formulations. Freezing should be avoided as it may alter suspension characteristics and reduce product uniformity. Storage in original containers protected from light helps maintain potency through the labeled expiration date.

Multi-dose vial handling requires aseptic technique to prevent contamination that could cause injection site infections or reduce product sterility. The rubber stopper should be wiped with alcohol before each needle entry. Using clean needles for each withdrawal prevents contamination transfer between the vial and previously treated animals. Recording the date of first use on the vial supports tracking product age, with vials discarded according to labeled instructions or within 28 days of opening, whichever comes first. Visual inspection before each use confirms acceptable appearance without particulate matter or color changes indicating degradation.

Thorough shaking before drawing each dose ensures uniform suspension of the crystalline penicillin complex throughout the vehicle. Penicillin G suspensions settle during storage, and failure to resuspend results in variable drug concentration between doses. Early withdrawals from inadequately shaken bottles may be subtherapeutic while later doses contain excess drug. Vigorous shaking until uniform appearance is achieved should precede every dose withdrawal. The relatively thick consistency of some formulations may require extended shaking for complete resuspension.

Disposal of expired, unused, or contaminated penicillin products follows standard pharmaceutical waste practices. Products should not be disposed of through regular trash or poured into water systems. Approved pharmaceutical waste channels, take-back programs, or specific agricultural waste disposal options should be utilized where available. Empty containers should be triple-rinsed and disposed of according to label directions. Proper disposal protects environmental quality and prevents inadvertent exposure of people or animals to pharmaceutical waste.

Species-specific penicillin G pharmacokinetics guide dosing across the various food animal species approved for treatment. Cattle receive the drug according to established protocols with consistent efficacy across beef and dairy breeds. Bos indicus breeds (Brahman and crosses) may show somewhat different drug handling than Bos taurus breeds based on general metabolic differences, though routine dose adjustments are not typically required. Individual animal factors including body condition, hydration status, and concurrent disease may influence drug distribution and response more significantly than breed alone.

Swine penicillin G use follows weight-based dosing consistent across commercial pig breeds and genetic lines. Modern lean genotypes receive standard dosing without modification. Heritage or specialty breeds without extensive pharmacokinetic evaluation may be treated following standard protocols with appropriate monitoring for response. The rapid growth rate of commercial swine makes accurate weight estimation particularly important for achieving therapeutic doses, as underdosing risks treatment failure while promoting resistance selection.

Sheep and goat treatment with penicillin G employs comparable per-kilogram dosing to cattle, recognizing that limited species-specific pharmacokinetic data exists for some formulations. Goats may metabolize certain drugs faster than sheep, leading some clinicians to use modestly higher doses or more frequent administration in goats, though evidence specifically supporting this approach for penicillin G is limited. Attention to individual animal response guides any needed adjustments. Wool breeds, hair sheep, dairy goats, and meat goats all receive standard protocols with equivalent expectations for response.

Production stage considerations influence penicillin G use independent of breed. Lactating dairy animals require attention to milk withdrawal with corresponding economic impact of discarded milk. Pregnant animals can safely receive penicillin G, which does not demonstrate teratogenic effects at therapeutic doses. Young animals including calves, lambs, kids, and piglets are appropriate treatment candidates with weight-adjusted dosing. Breeding animals and animals close to slaughter require consideration of withdrawal time compliance before treatment initiation.

Aminopenicillins including ampicillin and amoxicillin provide extended-spectrum alternatives with activity against some gram-negative organisms that natural penicillins do not cover. These semisynthetic penicillins maintain gram-positive activity comparable to penicillin G while adding effectiveness against organisms like Escherichia coli, Haemophilus species, and some Pasteurella. When mixed infections involving both gram-positive and gram-negative pathogens are suspected, aminopenicillins may offer advantages over penicillin G. However, aminopenicillins share susceptibility to beta-lactamase inactivation with penicillin G, limiting their effectiveness against resistant staphylococci.

Beta-lactamase-resistant penicillins such as cloxacillin and oxacillin address penicillin G's vulnerability to staphylococcal penicillinase. These isoxazolyl penicillins are specifically designed with side chains that sterically protect the beta-lactam ring from enzymatic hydrolysis. When staphylococcal infections are confirmed or strongly suspected based on clinical presentation, beta-lactamase-resistant penicillins provide more reliable coverage than penicillin G. In food animal medicine, these agents are primarily available as intramammary formulations for mastitis treatment.

Cephalosporin antibiotics offer alternative beta-lactam options with varying spectra depending on generation. First-generation cephalosporins provide gram-positive coverage similar to penicillin G with added beta-lactamase stability. Third-generation cephalosporins like ceftiofur extend activity to important gram-negative respiratory pathogens while maintaining gram-positive coverage. Selection among beta-lactam options considers the likely pathogens, susceptibility patterns, available formulations, withdrawal times, and antimicrobial stewardship principles favoring narrower-spectrum agents when appropriate.